NXTCL logo

NextCell Pharma AB Stock Price

OM:NXTCL Community·SEK 139.2m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

NXTCL Share Price Performance

SEK 1.25
0.16 (14.68%)
SEK 1.25
0.16 (14.68%)
Price SEK 1.25

NXTCL Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Moderate risk with adequate balance sheet.

5 Risks
1 Reward

NextCell Pharma AB Key Details

SEK 9.2m

Revenue

SEK 7.7m

Cost of Revenue

SEK 1.6m

Gross Profit

SEK 43.2m

Other Expenses

-SEK 41.6m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-0.37
16.97%
-449.88%
0%
View Full Analysis

About NXTCL

Founded
2014
Employees
24
CEO
Mathias Svahn
WebsiteView website
www.nextcellpharma.com

NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is headquartered in Huddinge, Sweden.

Recent NXTCL News & Updates

Recent updates

No updates